Mankind Pharma Ltd
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
- Market Cap ₹ 95,968 Cr.
- Current Price ₹ 2,325
- High / Low ₹ 3,055 / 1,901
- Stock P/E 50.9
- Book Value ₹ 355
- Dividend Yield 0.00 %
- ROCE 17.0 %
- ROE 15.5 %
- Face Value ₹ 1.00
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 58.4 days to 100 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 Nifty 500 Nifty Pharma
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
3,918 | 3,829 | 4,794 | 5,523 | 7,486 | 8,127 | 9,265 | 9,498 | |
3,141 | 3,124 | 3,550 | 4,151 | 5,644 | 6,429 | 6,939 | 6,935 | |
Operating Profit | 778 | 705 | 1,244 | 1,372 | 1,842 | 1,698 | 2,326 | 2,563 |
OPM % | 20% | 18% | 26% | 25% | 25% | 21% | 25% | 27% |
209 | 64 | 94 | 154 | 200 | 163 | 267 | 554 | |
Interest | 18 | 40 | 11 | 8 | 48 | 28 | 15 | 372 |
Depreciation | 28 | 38 | 62 | 78 | 123 | 270 | 318 | 378 |
Profit before tax | 941 | 691 | 1,265 | 1,440 | 1,871 | 1,563 | 2,260 | 2,367 |
Tax % | 26% | 26% | 24% | 25% | 26% | 20% | 19% | 18% |
694 | 514 | 958 | 1,084 | 1,389 | 1,248 | 1,823 | 1,945 | |
EPS in Rs | 17.33 | 12.83 | 23.92 | 27.07 | 34.68 | 31.16 | 45.52 | 47.15 |
Dividend Payout % | -0% | -0% | 32% | -0% | -0% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 8% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 12% |
TTM: | 10% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 6% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 17% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 41 |
Reserves | 2,957 | 3,025 | 3,611 | 4,694 | 6,500 | 7,744 | 9,584 | 14,599 |
360 | 190 | 3 | 101 | 688 | 5 | 9 | 7,254 | |
652 | 596 | 877 | 1,045 | 1,710 | 1,583 | 1,785 | 1,934 | |
Total Liabilities | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,418 | 23,828 |
534 | 778 | 945 | 987 | 2,927 | 3,142 | 3,404 | 3,487 | |
CWIP | 322 | 211 | 148 | 166 | 387 | 495 | 188 | 191 |
Investments | 1,402 | 1,698 | 1,784 | 2,397 | 2,526 | 3,102 | 4,430 | 16,683 |
1,751 | 1,164 | 1,655 | 2,330 | 3,100 | 2,632 | 3,396 | 3,467 | |
Total Assets | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,418 | 23,828 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
540 | 537 | 960 | 983 | 821 | 1,799 | 1,983 | 2,322 | |
-516 | -306 | -396 | -1,127 | -1,360 | -1,041 | -1,919 | -12,115 | |
8 | -240 | -559 | 89 | 579 | -710 | -9 | 9,845 | |
Net Cash Flow | 31 | -9 | 5 | -55 | 40 | 48 | 55 | 53 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 23 | 13 | 32 | 24 | 23 | 22 | 30 | 34 |
Inventory Days | 120 | 126 | 124 | 169 | 183 | 132 | 135 | 153 |
Days Payable | 115 | 101 | 113 | 122 | 133 | 103 | 107 | 79 |
Cash Conversion Cycle | 27 | 38 | 43 | 72 | 73 | 52 | 58 | 108 |
Working Capital Days | 95 | 44 | 41 | 49 | 60 | 40 | 35 | 100 |
ROCE % | 22% | 36% | 33% | 30% | 21% | 25% | 17% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16 Jun
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
10 Jun - Allotment of 57,709 Equity Shares under Mankind Employee Stock Option Plan 2022
-
Intimation Under Regulations 30 & 51 Of SEBI (LODR) Regulations, 2015 - Environmental, Social And
Governance (ESG) Rating
4 Jun - ISS ESG assigned Mankind Pharma an ESG score of 38.98 (C-) on June 3, 2025.
-
Announcement under Regulation 30 (LODR)-Acquisition
2 Jun - Incorporation of wholly owned subsidiary KINDCARE FOUNDATION on June 2, 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
27 May - Mankind Pharma Q4 FY25 revenue up 27%, FY25 revenue INR12,207 Cr, BSV acquisition integrated, EBITDA margin ~25.9%.
Concalls
-
May 2025Transcript PPT
-
Jan 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Sep 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jul 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
Leadership[1]
- 1 Rank in Prescriptions over the last 5 yrs.
- Youngest in the Top 5 of the IPM
- 4 By value in the IPM
- 4 Consumer Healthcare brands Market ranked
1 in their categories